Spatial and temporal diversity in genomic instability processes defines lung cancer evolution by Bruin, Elza C de et al.
Spatial and temporal diversity in genomic instability processes 
defines lung cancer evolution
Elza C. de Bruin1,*, Nicholas McGranahan2,3,*, Richard Mitter2,*, Max Salm2,*, David C. 
Wedge4,*, Lucy Yates4,5,†, Mariam Jamal-Hanjani1,†, Seema Shafi1, Nirupa Murugaesu1, 
Andrew J. Rowan2, Eva Grönroos2, Madiha A. Muhammad1, Stuart Horswell2, Marco 
Gerlinger2, Ignacio Varela6, David Jones4, John Marshall4, Thierry Voet4,7, Peter Van 
Loo4,7, Doris M. Rassl8, Robert C. Rintoul8, Sam M. Janes9, Siow-Ming Lee1,10, Martin 
Forster1,10, Tanya Ahmad10, David Lawrence10, Mary Falzon10, Arrigo Capitanio10, Timothy 
T. Harkins11, Clarence C. Lee11, Warren Tom11, Enock Teefe11, Shann-Ching Chen11, 
Sharmin Begum2, Adam Rabinowitz2, Benjamin Phillimore2, Bradley Spencer-Dene2, 
Gordon Stamp2, Zoltan Szallasi12,13, Nik Matthews2, Aengus Stewart2, Peter Campbell4, 
and Charles Swanton1,2,‡
1Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer 
Institute, London WC1E 6BT, UK
2Cancer Research UK London Research Institute, London WC2A 3LY, UK
3Centre for Mathematics and Physics in the Life Science and Experimental Biology (CoMPLEX), 
University College London, London WC1E 6BT, UK
4Wellcome Trust Sanger Institute, Hinxton, CB10 1SA, UK
5University of Cambridge, Cambridge CB2 1TN, UK
6Instituto de Biomedicina y Biotecnología de Cantabria (CSIC-UC-Sodercan), Departamento de 
Biología Molecular, Universidad de Cantabria, Santander, Spain
7Department of Human Genetics, University of Leuven, 3000 Leuven, Belgium
8Papworth Hospital NHS Foundation Trust, Cambridge CB23 3RE, UK
9Lungs for Living Research Centre, University College London, London WC1E 6BT, UK
10University College London Hospitals, London NW1 2BU, UK
11Thermo Fisher Scientific, Carlsbad, CA 92008, USA
12Technical University of Denmark, 2800 Kongens Lyngby, Denmark
Permission to republish or repurpose articles or portions of articles can be obtained by following the guidelines here.
‡Corresponding author. charles.swanton@cancer.org.uk.
*These authors contributed equally to this work.




Figs. S1 to S14
Tables S1 to S4
References (38–64)
Europe PMC Funders Group
Author Manuscript
Science. Author manuscript; available in PMC 2015 November 06.
Published in final edited form as:













13Children’s Hospital Informatics Program, Harvard Medical School, Boston, MA 02115, USA
Abstract
Spatial and temporal dissection of the genomic changes occurring during the evolution of human 
non–small cell lung cancer (NSCLC) may help elucidate the basis for its dismal prognosis. We 
sequenced 25 spatially distinct regions from seven operable NSCLCs and found evidence of 
branched evolution, with driver mutations arising before and after subclonal diversification. There 
was pronounced intratumor heterogeneity in copy number alterations, translocations, and 
mutations associated with APOBEC cytidine deaminase activity. Despite maintained carcinogen 
exposure, tumors from smokers showed a relative decrease in smoking-related mutations over 
time, accompanied by an increase in APOBEC-associated mutations. In tumors from former 
smokers, genome-doubling occurred within a smoking-signature context before subclonal 
diversification, which suggested that a long period of tumor latency had preceded clinical 
detection. The regionally separated driver mutations, coupled with the relentless and 
heterogeneous nature of the genome instability processes, are likely to confound treatment success 
in NSCLC.
Lung cancer is the leading cause of cancer-related mortality (1, 2). Understanding the 
pathogenesis and evolution of lung cancer may lead to greater insight into tumor initiation 
and maintenance and may guide therapeutic interventions. Previous work characterizing the 
genome of non–small cell lung cancer (NSCLC) has demonstrated that NSCLC genomes 
exhibit hundreds of nonsilent mutations together with copy number aberrations and genome 
doublings (3-9). Although subclonal populations have been identified within single biopsies 
(9), the extent of genomic diversity within primary NSCLCs remains unclear. Moreover, 
although both exogenous mutational processes, such as smoking (10-12), and endogenous 
processes, such as up-regulation of APOBEC cytidine deaminases (13-15), have been found 
to contribute to the large mutational burden in NSCLC, the temporal dynamics of these 
processes and their contribution to driver somatic aberrations over time remain unknown.
To investigate lung cancer evolution, we performed multiregion whole-exome and/or whole-
genome sequencing (M-seq WES/WGS) on a total of 25 tumor regions, collected from 
seven NSCLC patients who underwent surgical resection before receiving adjuvant therapy. 
The major NSCLC histological subtypes, including adenocarcinoma (LUAD) and squamous 
cell carcinoma (LUSC), were represented (table S1). Sequencing of tumor and normal DNA 
to mean coverage depths of 107× and 54× for M-seq WES and M-seq WGS, respectively 
(table S2), identified 1884 nonsilent and 76,129 silent mutations (16).
To evaluate the intratumor heterogeneity of nonsilent mutations, we classified each mutation 
as ubiquitous (present in all tumor regions) or heterogeneous (present in at least one, but not 
all, regions). Spatial intratumor heterogeneity was identified in all seven NSCLCs, with a 
median of 30% heterogeneous mutations (range 4 to 63%) (Fig. 1A and fig. S1). In the 
adenosquamous tumor from patient L002, heterogeneous mutations separated concordant 
with LUAD (regions R1 and R2) or LUSC (regions R3 and R4) histopathologies (fig. S2). 
Patients L003 and L008 each presented with two tumors in separate lobes of the lung. M-seq 
WES revealed 74% ubiquitous mutations in the tumors from L008, which indicated a clonal 
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origin. However, in L003, only a single mutation (EGFRL858R, the epidermal growth factor 
receptor in which Leu858 is replaced with Arg) was detected in both tumors (Fig. 1A). Given 
that EGFRL858R is a highly recurrent mutation (17) and also that no silent mutations were 
shared, we concluded that the tumors in L003 were of independent clonal origin, with the 
evolution of identical oncogenic events in parallel.
To resolve the extent of genomic diversity in NSCLC and to infer the ancestral relations 
between tumor regions, we estimated the fraction of tumor cells within each region 
harboring each mutation (16, 18). Almost all ubiquitous mutations (>99%) were classified as 
fully clonal within each region. Moreover, in most regions, the majority of heterogeneous 
mutations was clonal and, thus, present in all cells within the region (Fig. 1B and fig. S3). 
However, certain regions displayed considerable subclonal diversity. For example, >75% of 
heterogeneous mutations present in L004 R5 were subclonal (Fig. 1B), and this region 
consisted of two distinct subclonal populations. The subclonal structure of each tumor 
region was then used to construct phylogenetic trees, by using both maximum parsimony 
and unweighted pair-group methods. We also took into account regional copy number losses 
that resulted in shared truncal mutations becoming heterogeneous later in tumor evolution 
(16), such as a segment of chromosome 6 in LS01 (fig. S4) and the PAX7 mutation in the 
lymph node of L001 (Fig. 1A). Notably, all seven NSCLCs showed evidence of branched 
tumor evolution (fig. S5).
We next evaluated the regional heterogeneity of potential NSCLC driver mutations, 
classified into three categories on the basis of current evidence supporting driver mutation 
status (16). Every tumor showed evidence for ubiquitous, as well as heterogeneous, driver 
mutations, many of which were clonally dominant in a subset of tumor regions and entirely 
absent in others (Fig. 1B, fig. S3, and table S3). Note that the probability of missing a 
category 1 “high-confidence” driver gene by analyzing a single region for each tumor was 
on average 42% (range 0 to 67%) and 83% (range 67 to 100%) for all potential driver genes 
(categories 1 to 3), which highlights the potential limitations of assessing single tumor 
regions. Nevertheless, category 1 and 2 driver mutations were significantly more often 
truncal compared with mutations in nondriver genes in our M-seq analysis (P = 0.04). 
Consistent with these data, in The Cancer Genome Atlas (TCGA) cohort, previously 
reported driver genes (5, 19, 20) were significantly enriched for clonal mutations (P < 0.001) 
(fig. S6). These data indicate that, in NSCLC, most known driver mutations occur early in 
tumor evolution.
To determine the intratumor heterogeneity of copy number aberrations, we estimated integer 
DNA copy numbers for each tumor region (7, 16, 21, 22). A large fraction of the genome 
had undergone alterations in all tumors, and genomic profiles were more similar within 
tumors than between different tumors (fig. S7). To evaluate the spatial heterogeneity of 
potential tumor driver copy number aberrations, we explored the regional distribution of 
chromosomal segments identified as recurrently gained or lost in TCGA LUAD or LUSC 
tumors. Most segments were identified as aberrant in at least one tumor region, and many 
recurrent gains and losses were found to be heterogeneous in at least one tumor (Fig. 2A). 
For example, in L001, a focal EGFR amplification (chr7p11.2), as well as deletions of 
chromosomal segments harboring CDKN2A (chr9p21.3) and PTEN (chr10q23.31), was 
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observed in all regions, whereas, in L008, we observed heterogeneous copy number losses 
involving CDKN2A and PTEN. In support of copy number aberrations occurring later in 
tumor development, we also identified subclonal copy number aberrations within tumor 
regions. For instance, more than 15% of the genome in region R1 of L008 was subject to 
subclonal copy number alterations (fig. S8). Consistent with evidence of subclonal copy 
number aberrations, centromeric fluorescence in situ hybridization analyses confirmed 
numerical chromosomal diversity within individual tumor regions (fig. S9), which suggested 
that chromosomal instability may provide a substrate for subclonal competition.
The high-coverage M-seq WGS (mean 96×) for L002 and L008 enabled us to investigate the 
regional separation of large-scale genomic events in these samples. For the adenosquamous 
tumor L002, we identified 30 structural variants, most of which were found either in the 
LUAD region R1 or the LUSC region R3, but not both (table S4), which suggested that they 
occurred after subclonal diversification (Fig. 2B). By contrast, for L008, 48 of the 52 
identified structural variants were shared between the two tumor regions from different 
lobes of the lung, which suggested that the majority of these variants occurred before tumor 
metastasis to the other lobe (Fig. 2B). Notably, in L008, “chains” of translocations with 
highly clustered breakpoints were found between chromosomes 14 and 17, as well as 
chromosomes 17 and 19 (fig. S10 and table S4), which disrupted the FANCM and NF1 
tumor suppressor genes. Breakpoint homology profiling suggests involvement of either 
nonhomologous or alternative end-joining (23, 24), indicative of double-strand break events. 
This lesion pattern is consistent with chromoanagenesis (25) and indicates a punctuated 
evolution pattern where multiple oncogenic events may have occurred simultaneously (26).
Four tumors displayed evidence for whole-genome–doubling events (16). In three tumors 
(L001, L004, and L008), the genome-doubling event was shared across every tumor region; 
it occurred before diversification, with the majority of truncal mutations (84 to 88%) present 
at ploidy ≥2, indicative of a large mutational burden before genome doubling. In one tumor, 
L002, the majority of heterogeneous mutations were also present at ploidy ≥2, indicative of 
two independent genome-doubling events: one in the LUAD region and one in the LUSC 
region (fig. S11). Notably, every truncal driver mutation likely occurred before genome 
doubling.
To further explore the dynamics of the mutational processes shaping lung cancer genomes 
over time, the spectra of point mutations in each tumor were temporally dissected. Early 
(truncal) mutations likely reflect processes involved before and during tumor initiation and 
early development, whereas late (branched) mutations reveal mutational processes shaping 
the genome during tumor maintenance and progression, including those contributing to 
intratumor heterogeneity. For L002, we analyzed regions R1 and R3 separately to allow 
comparisons of LUAD and LUSC histologies within the same tumor.
In all tumors, we observed statistically significant shifts in the mutation spectra over time (P 
< 0.05 all cases) (Fig. 3A). Furthermore, every tumor exhibited a statistically significant 
decrease in the proportion of C>A transversions in late compared with early mutations (P < 
0.05) (Fig. 3A), although this was more pronounced in the LUAD cases [mean odds ratio: 
LUAD 3.13 (range 2.07 to 5.55) and LUSC 1.34 (range 1.21 to 1.46)]. Because C>A 
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transversions are associated with the mutagenic effects of tobacco smoke (12), a decrease in 
the proportion of C>A transversions indicates a relative decrease in the mutational burden 
attributable to smoking during LUAD development, in both former smokers and current 
smokers.
To validate these observations in a larger NSCLC cohort, mutations in TCGA LUAD and 
LUSC samples were temporally dissected (16). Consistent with our M-seq analyses, both 
TCGA LUAD and LUSC smokers and former smokers exhibited a decrease in the 
proportion of C>A transversions in late mutations (LUAD current smokers, P < 0.0001; 
former smokers, P < 0.0001; never-smokers, P = 0.147; LUSC current smokers, P = 0.003; 
former smokers, P < 0.0001; and never-smokers, P = 0.673) (Fig. 3B). Similarly, the least-
pronounced decrease was observed in LUSC current smokers; 25% of LUSC displayed no 
decrease in C>A transversions, compared with less than 10% in LUAD. The mutational 
footprint of smoking exhibits a strand bias with C>A transversions accumulating 
preferentially on the transcribed strand (10, 12). Both LUAD and LUSC former smokers 
revealed a statistically significant decrease in strand bias in late, compared with early, C>A 
transversions (LUAD, P = 0.00354; LUSC, P = 0.046), consistent with an ancestral footprint 
of smoking on these genomes. Conversely, no statistically significant difference was 
observed between early and late mutations in current smokers (LUAD, P = 0.23; LUSC, P = 
0.22).
In the majority of M-seq tumors, the decreased proportion of C>A mutations was 
accompanied by an increase in C>T and C>G mutations at TpC sites, indicative of 
APOBEC cytidine deaminase activity (13-15). Mutations consistent with APOBEC-
mediated mutagenesis were more pronounced on the branches than the trunk in four out of 
five LUAD M-seq samples (Fig. 3C). On average 31% (8 to 41%) of nonsilent branch 
mutations occurred in an APOBEC-mutation context compared with 11% (7 to 16%) of 
truncal nonsilent mutations. Branched driver genes PIK3CA, EP300, TGFBR1, PTPRD, and 
AKAP9 harbored mutations in an APOBEC context, which indicated a possible functional 
impact of APOBEC activity on subclonal expansion. Likewise, TCGA LUAD tumors with 
detectable APOBEC mutational signatures showed significant enrichment in late, compared 
with early, APOBEC mutations (P < 0.001) (fig. S12), and 20% of subclonal driver 
mutations were found to occur in an APOBEC context, compared with 11% of clonal driver 
mutations. However, for TCGA LUSC tumors with detectable APOBEC mutational 
signatures, temporal dissection of APOBEC mutations did not reveal such a clear trend (fig. 
S12), which indicated potential differences in the temporal dynamics of APOBEC-mediated 
mutagenesis between histological subtypes. In addition to temporal heterogeneity, spatial 
heterogeneity in both the proportion of APOBEC-associated mutations (Fig. 3, D and E) and 
APOBEC mRNA expression was observed in the M-seq tumors (fig. S13).
To gain a deeper understanding of NSCLC evolution, we focused on the two tumors with 
high-coverage M-seq WGS and temporally placed the genomic instability processes relative 
to the emergence of the most-recent common ancestor (Fig. 4). In patient L002, a current 
smoker, tobacco carcinogens played a significant role early in tumor development, with 
C>A transversions representing 39% of truncal mutations (Fig. 4A). Early mutations 
included multiple driver genes, such as TP53 and CHD8. Upon diversification into a LUAD 
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subclone and a LUSC subclone, copy number alterations (fig. S7) and driver mutations were 
acquired independently in both subclones, such as a stop-gain mutation in the tumor 
suppressor gene FAT1 on the LUSC branch and mutations affecting TGFBR1, ZFHX4, 
ARHGAP35, and PTPRD in the LUAD region. APOBEC-associated mutations were 
elevated specifically in the LUAD region, which included the driver mutations in TGFBR1 
and PTPRD, and the highest APOBEC3B mRNA expression was detected in this region (fig. 
S13).
The tumors from patient L008 also displayed truncal C>A transversions and spatial 
heterogeneity in APOBEC enrichment, with a more pronounced APOBEC signature in the 
tumor of the middle lobe compared with the upper lobe (Fig. 4B). In L008, we gained 
further temporal resolution by exploring the mutations before and after the truncal genome-
doubling event. All truncal driver mutations were found to occur before genome doubling. 
However, a tobacco smoke signature of C>A transversions was observed in more than 30% 
of truncal mutations both before and after doubling, and only in 21% and 9% of 
heterogeneous mutations in the two regions R1 and R3 from separate lobes of the lung. 
Because L008 ceased smoking more than 20 years before surgery (table S1), these data 
suggest that the genome-doubling event and truncal driver mutations occurred within a 
smoking carcinogenic context more than 20 years ago. Similarly, the genome-doubling 
event and truncal driver mutations in former smoker L001 also appeared to occur before 
smoking cessation more than 20 years before surgery (fig. S14). These data suggest a 
prolonged tumor latency period after genome doubling and before clinical detection in 
NSCLC.
Through sequencing multiple surgically resected tumor regions, we were able to unravel 
both the extent of genomic heterogeneity and the evolutionary history of seven NSCLCs. In 
contrast to the situation in clear cell renal cell carcinoma (ccRCC) (27, 28), known driver 
mutations typically occurred early in NSCLC development, and the majority of high-
confidence driver events were fully clonal. Conceivably, this explains the progression-free 
survival benefits associated with NSCLC oncogenic driver targeting (29). However, like 
ccRCC (27, 28), all NSCLCs exhibited heterogeneous driver mutations and/or recurrent 
copy number aberrations and many heterogeneous mutations gave the “illusion of clonality,” 
as they are present in all cells from certain regions but undetectable within other regions. 
Notably, although our multiregional sampling approach allowed us to evaluate spatial 
heterogeneity, only a small part of the entire tumor was sampled (on average <5%), which 
indicates that we might be underestimating the full extent of heterogeneity in these tumors.
Conceivably, intratumor heterogeneity may compromise the ability of a single biopsy to 
define all driver events comprehensively for optimal tumor control. For instance, L008 
presented with an activating BRAF (G469A) mutation (30) in all regions and an activating 
PIK3CA (E542K) mutation (31) only in region R3. Thus, a biopsy taken from R3 might 
suggest treatment with an inhibitor of the phosphatidylinositol 3-kinase–mammalian target 
of rapamycin (PI3K/mTOR) signaling axis and combination therapy. Conversely, a single 
biopsy from any other region would suggest treatment with a BRAF inhibitor, for which the 
tumor cells from R3 might be resistant because of the PIK3CA mutation (32).
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Our study also sheds light on the divergent genomic instability processes involved in 
NSCLC evolution and their dynamics over time. Evidence for spatial diversity in genomic 
instability processes suggests that opportunities to exploit such mechanisms therapeutically 
may be limited in this disease (33). In three tumors, we detected genome-doubling events 
occurring before subclonal diversification but after acquisition of driver mutations, 
consistent with findings in colorectal cancer that genome doubling may accelerate cancer 
genome evolution (34). The relation of chromosomal instability with drug resistance and 
early tumor recurrence (35, 36) suggests that targeting truncal driver events may be 
compromised by the initiation of chromosomal instability later in tumor evolution. These 
results, coupled with the observation that NSCLC tumors may have prolonged latency 
periods, support continued efforts to optimize methods for earlier detection.
Unexpectedly, we found that despite continuous exposure to the mutagens in tobacco 
smoke, tumors from smokers showed evidence that an additional genomic instability process 
(APOBEC-associated mutagenesis) likely contributes to tumor progression. A large 
proportion of subclonal driver mutations were found to occur in an APOBEC context, which 
suggests that the differences in mutation spectra over time and space may reflect the activity 
of the process generating the mutations, as well as the selective advantage of the acquired 
mutations.
The presence of subclonal, regionally separated driver events, coupled with the relentless 
and dynamic nature of genomic instability processes observed in this study, highlight the 
therapeutic challenges associated with NSCLC. Engaging an adaptable immune system may 
present a tractable approach to manage the dynamic complexity in NSCLC (37). 
Longitudinal studies will be required to decipher drivers of subclonal expansion, identify the 
origins of subclones contributing to metastatic recurrence, and resolve the evolutionary 
principles that underpin the dismal outcome associated with this disease.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Intratumor heterogeneity of somatic mutations in human NSCLC
(A) Heat maps show the regional distribution of all nonsilent mutations; presence (blue) or 
absence (gray) of each mutation is indicated for every tumor region. Cartoons depict the 
location of each tumor. Column next to heat map shows the intratumor heterogeneity; 
mutation present in all regions (blue), in more than one but not all (yellow), or in one region 
(red). Mutations are ordered on tumor driver category with categories 1 to 3 indicated in the 
right column in black, dark gray, and light gray, respectively (details in table S3). Total 
number of nonsilent mutations is provided below each tumor with percentage of 
heterogeneous mutations in brackets. In L001, the mutation marked by an asterisk (*) is 
additional to the germline MEN1 mutation. LN, lymph node; R, region. (B) Two-
dimensional Dirichlet plots show the cancer cell fraction (CCF) of the mutations in all 
regions of tumors L004; increasing intensity of red indicates the location of a high posterior 
probability of a cluster. In region R5, the majority of heterogeneous mutations are subclonal, 
and a cluster of mutations with a CCF below 1 can be observed.
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Fig. 2. Intratumor heterogeneity of chromosomal alterations in human NSCLC
(A) Distribution of potential tumor driver copy number alterations is indicated for each 
tumor region. The upper heat maps show the regional distribution of recurrently amplified 
(left) or deleted (right) chromosomal segments based on TCGA LUAD data, and the lower 
heat maps show the regional distribution of recurrently amplified or deleted chromosomal 
segments based on TCGA LUSC data. For each region, gain (red) or loss (blue) was 
determined relative to the mean ploidy. (B) Circos plots depicting inter- and 
intrachromosomal translocations, as well as deletions and insertions for regions R1 and R3 
for L002 (upper) and L008 (lower); shared events are indicated in blue, events private to 
region R1 are indicated in red, and private to region R3 in green. The outer circle represents 
the integer copy number data for R1 and the inner circle for R3 for each tumor sample; copy 
number segments with an integer value greater than mean ploidy are in red and those less 
than mean ploidy in blue.
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Fig. 3. Temporal and spatial dissection of mutation spectra in LUAD and LUSC samples
(A) Fraction of early mutations (trunk) and late mutations (branch) accounted for by each of 
the six mutation types in all M-seq samples. (B) Beeswarm plots showing the fraction of 
early mutations and late mutations accounted for by each of the six mutation types in every 
TCGA former smoker or current smoker with both early and late mutations. Significance is 
indicated. (C) APOBEC mutation enrichment odds ratio for early (trunk, blue bars) and late 
(branch, red bars) mutations for M-seq samples. The APOBEC signature encompasses C>T 
and C>G mutations in a TpC context (16).The 95% confidence intervals for Fisher’s exact 
test are indicated. (D and E) Three mutation types (C>A; C>G and C>T) at all 16 possible 
trinucleotide contexts for L002 (D) and L008 (E). For both samples, trunk mutations as well 
as branch mutations from two regions are depicted.
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Fig. 4. A model of the evolutionary history of NSCLC
Evolutionary histories of tumors from patients L002 (A) and L008 (B) are depicted. 
Genomic instability processes defining NSCLC evolution have been placed on their 
phylogenetic trees. Driver mutations occurring in an APOBEC context are highlighted with 
a blue box, and those occurring in a smoking context with a gray box. In each case, the 
timing of genome-doubling events is indicated with an arrow. CIN, chromosomal instability; 
muts, mutations.
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